Browse diseases

…le-arm phase II trial, patients with resectable stage IIIA–IIIB NSCLC received three cycles of camrelizumab plus chemotherapy, follow…

…comparison to VATS, on overall survival in operable early stage NSCLC patients.Methods and analysis Data on NSCLC patients will be co…

…patient enrollment. Patients were included if they had advanced NSCLC, and were first-time users of immune checkpoint inhibitor (ICI)…

…cases of cardiotoxicity induced by osimertinib in patients with non-small-cell lung cancer (NSCLC). However, limited data exist for a comprehensive cardio…

…apy has transformed the therapeutic landscape for patients with non-small cell lung cancer (NSCLC), critical questions remain regarding how detailed smoki…

… (CRT) (n=25) and (2) a matched control cohort of patients with NSCLC who had neoadjuvant CRT only (n=25). TDLN were classified based…

…bjective response rate (ORR).Results Twenty-seven patients with PD-L1-negative NSCLC treated with chemoimmunotherapy were included. At a median foll…

…plet study of plinabulin/docetaxel/pembrolizumab for metastatic NSCLC immediately after progression on immune-checkpoint-inhibitor al…

…onclusions A CT-based radiomic signature restricted to stage IV NSCLC provides robust, time-specific prognostic information and accur…

…ll cell lung cancer (NSCLC). Mutations in STK11 occur in 20% of NSCLC and are associated with poor responsiveness to anti-PD-1 agents…

…monstrates that layered spatial and functional profiling of the NSCLC TME reveals key prognostic markers linked to immunotherapy resp…

…f mutation prevalence in each IRP. In the immunotherapy-treated NSCLC cohort, we found significant association between IRP and overal…